Innovating Healthcare Solutions

In early 2026, CooperSurgical launched the Select Syndrome Screen℠ Test, which detects specific additional genetic abnormalities before embryo transfer and includes 10 impactful genetic disorders that may significantly impact a child’s health or development.

CooperSurgical’s comprehensive genetic testing services focus on testing for all aspects of the preimplantation journey.

The first and only FDA-approved soft contact lens proven to slow the progression of myopia (nearsightedness) in children, aged 8-12 at the initiation of treatment.

Cooper spearheads scientific and technological breakthroughs through advanced research and development (R&D).

CooperSurgical provides practice-enhancing tools that advance standards of care in hospitals, surgical centers, medical offices and fertility clinics.